IDENTIFICATION OF HORMONAL PARAMETERS FOR SUCCESSFUL SYSTEMIC SINGLE-DOSE METHOTREXATE THERAPY IN ECTOPIC PREGNANCY

Citation
Gh. Corsan et al., IDENTIFICATION OF HORMONAL PARAMETERS FOR SUCCESSFUL SYSTEMIC SINGLE-DOSE METHOTREXATE THERAPY IN ECTOPIC PREGNANCY, Human reproduction, 10(10), 1995, pp. 2719-2722
Citations number
11
Categorie Soggetti
Reproductive Biology
Journal title
ISSN journal
02681161
Volume
10
Issue
10
Year of publication
1995
Pages
2719 - 2722
Database
ISI
SICI code
0268-1161(1995)10:10<2719:IOHPFS>2.0.ZU;2-C
Abstract
Single-dose methotrexate is an alternative to surgery in treating ecto pic pregnancy, Because success rates vary, we sought to identify facto rs which predict treatment outcome, A total of 44 women with ectopic g estation were treated, The non-laparoscopic diagnosis of ectopic pregn ancy was made following history, physical examination, ultrasound, end ometrial biopsy and the measurement of serial beta-human chorionic gon adotrophin (HCG) and progesterone concentrations, Methotrexate (50 mg/ m(2) i.m.) was administered, with a second dose given 1 week later in patients with plateauing or rising beta-HCG concentrations, Of 44 pati ents, 23 (52.3%) were successfully treated with one dose, An additiona l 10 women (22.7%) were also successfully managed but required a secon d dose, giving an overall success rate of 75.0%, In all, 11 women (25. 0%) required surgery, four of whom experienced tubal rupture, Receiver operator curves were constructed to optimally select pretreatment bet a-HCG and progesterone cut-off concentrations for successful treatment , Using beta-HCG <1500 IU/l or progesterone <7.0 ng/ml (22.3 nmol/l) a s a cut-off concentration produced a diagnostic test with a sensitivit y of 87.5%, a specificity of 90.0%, a positive predictive value of 96. 6% and a negative predictive value of 69.2%. Conversely, this model pr edicts that patients with serum beta-HCG concentrations greater than o r equal to 1500 IU/l and progesterone concentrations greater than or e qual to 7.0 ng/ml are at far greater risk of failing single-dose metho trexate therapy.